CA2615420A1 - 2-arylbenzothiazoles et leurs utilisations - Google Patents

2-arylbenzothiazoles et leurs utilisations Download PDF

Info

Publication number: CA2615420A1
Authority: CA; Canada
Prior art keywords: group; alkyl; independently represents; aryl; benzothiazol
Prior art date: 2005-07-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002615420A

Other languages

English (en)

Inventor

Jan Ehlert

Thomas Herz

Rolf Krauss

Michael Kubbutat

Martin Lang

Wael Saeb

Christoph Schaechtele

Stefan Tasler

Frank Totzke

Ute Zirrgabel

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

4SC AG

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-15

Filing date

2006-05-16

Publication date

2007-01-25

2005-07-15 Priority claimed from EP05015432A external-priority patent/EP1746096A1/fr

2006-05-16 Application filed by Individual filed Critical Individual

2007-01-25 Publication of CA2615420A1 publication Critical patent/CA2615420A1/fr

Status Abandoned legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 claims abstract description 122
125000000217 alkyl group Chemical group 0.000 claims abstract description 63
125000003118 aryl group Chemical group 0.000 claims abstract description 50
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 34
150000003839 salts Chemical class 0.000 claims abstract description 29
125000001424 substituent group Chemical group 0.000 claims abstract description 20
239000000651 prodrug Substances 0.000 claims abstract description 12
229940002612 prodrug Drugs 0.000 claims abstract description 12
229910052717 sulfur Inorganic materials 0.000 claims abstract description 10
229910052760 oxygen Inorganic materials 0.000 claims abstract description 9
125000000623 heterocyclic group Chemical group 0.000 claims abstract description 8
125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 3
238000002360 preparation method Methods 0.000 claims description 44
125000000753 cycloalkyl group Chemical group 0.000 claims description 28
125000004093 cyano group Chemical group *C#N 0.000 claims description 26
229910052736 halogen Inorganic materials 0.000 claims description 26
150000002367 halogens Chemical class 0.000 claims description 26
125000004438 haloalkoxy group Chemical group 0.000 claims description 25
125000001188 haloalkyl group Chemical group 0.000 claims description 25
125000003282 alkyl amino group Chemical group 0.000 claims description 24
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 24
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 24
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 24
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 24
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
125000004432 carbon atom Chemical group C* 0.000 claims description 22
201000010099 disease Diseases 0.000 claims description 22
125000003545 alkoxy group Chemical group 0.000 claims description 21
239000003814 drug Substances 0.000 claims description 18
239000000460 chlorine Substances 0.000 claims description 17
229910052801 chlorine Inorganic materials 0.000 claims description 17
229910052731 fluorine Inorganic materials 0.000 claims description 15
125000004414 alkyl thio group Chemical group 0.000 claims description 14
229910052757 nitrogen Inorganic materials 0.000 claims description 13
238000011282 treatment Methods 0.000 claims description 13
206010028980 Neoplasm Diseases 0.000 claims description 12
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 12
230000005764 inhibitory process Effects 0.000 claims description 11
108091000080 Phosphotransferase Proteins 0.000 claims description 7
239000000654 additive Substances 0.000 claims description 7
102000020233 phosphotransferase Human genes 0.000 claims description 7
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 6
201000011510 cancer Diseases 0.000 claims description 6
125000005843 halogen group Chemical group 0.000 claims description 6
125000005842 heteroatom Chemical group 0.000 claims description 6
125000006574 non-aromatic ring group Chemical group 0.000 claims description 6
239000002671 adjuvant Substances 0.000 claims description 5
229910052794 bromium Inorganic materials 0.000 claims description 5
229910052799 carbon Inorganic materials 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 5
125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 4
241000282414 Homo sapiens Species 0.000 claims description 4
206010025323 Lymphomas Diseases 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 4
125000004103 aminoalkyl group Chemical group 0.000 claims description 4
125000001769 aryl amino group Chemical group 0.000 claims description 4
125000005191 hydroxyalkylamino group Chemical group 0.000 claims description 4
229910052740 iodine Inorganic materials 0.000 claims description 4
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 3
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
206010009944 Colon cancer Diseases 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
208000026278 immune system disease Diseases 0.000 claims description 3
208000027866 inflammatory disease Diseases 0.000 claims description 3
208000032839 leukemia Diseases 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
150000005749 2-halopyridines Chemical class 0.000 claims description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
208000023275 Autoimmune disease Diseases 0.000 claims description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
229910006069 SO3H Inorganic materials 0.000 claims description 2
125000002947 alkylene group Chemical group 0.000 claims description 2
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 2
125000000732 arylene group Chemical group 0.000 claims description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
210000000481 breast Anatomy 0.000 claims description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
208000035269 cancer or benign tumor Diseases 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
125000002993 cycloalkylene group Chemical group 0.000 claims description 2
239000011737 fluorine Substances 0.000 claims description 2
125000005549 heteroarylene group Chemical group 0.000 claims description 2
239000011630 iodine Substances 0.000 claims description 2
210000004072 lung Anatomy 0.000 claims description 2
239000001301 oxygen Substances 0.000 claims description 2
210000002307 prostate Anatomy 0.000 claims description 2
125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 claims description 2
206010005003 Bladder cancer Diseases 0.000 claims 1
206010006187 Breast cancer Diseases 0.000 claims 1
208000026310 Breast neoplasm Diseases 0.000 claims 1
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
208000024172 Cardiovascular disease Diseases 0.000 claims 1
208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
208000008839 Kidney Neoplasms Diseases 0.000 claims 1
206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
206010060862 Prostate cancer Diseases 0.000 claims 1
208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
206010038389 Renal cancer Diseases 0.000 claims 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
125000004450 alkenylene group Chemical group 0.000 claims 1
201000010982 kidney cancer Diseases 0.000 claims 1
201000005202 lung cancer Diseases 0.000 claims 1
208000020816 lung neoplasm Diseases 0.000 claims 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
208000015122 neurodegenerative disease Diseases 0.000 claims 1
201000002528 pancreatic cancer Diseases 0.000 claims 1
208000008443 pancreatic carcinoma Diseases 0.000 claims 1
201000005112 urinary bladder cancer Diseases 0.000 claims 1
125000002877 alkyl aryl group Chemical group 0.000 abstract 1
-1 Aurora-A Proteins 0.000 description 77
239000000203 mixture Substances 0.000 description 66
238000000034 method Methods 0.000 description 56
238000003786 synthesis reaction Methods 0.000 description 54
230000015572 biosynthetic process Effects 0.000 description 52
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 39
239000000047 product Substances 0.000 description 39
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
229910001868 water Inorganic materials 0.000 description 33
210000004027 cell Anatomy 0.000 description 31
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
102000001253 Protein Kinase Human genes 0.000 description 24
108060006633 protein kinase Proteins 0.000 description 24
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
WKRCOZSCENDENK-UHFFFAOYSA-N 4-(1,3-benzothiazol-2-yl)aniline Chemical class C1=CC(N)=CC=C1C1=NC2=CC=CC=C2S1 WKRCOZSCENDENK-UHFFFAOYSA-N 0.000 description 21
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
239000000243 solution Substances 0.000 description 20
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 18
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
238000006243 chemical reaction Methods 0.000 description 18
239000012071 phase Substances 0.000 description 18
239000000843 powder Substances 0.000 description 18
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
150000001412 amines Chemical class 0.000 description 16
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 15
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
239000007787 solid Substances 0.000 description 15
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
239000012267 brine Substances 0.000 description 12
230000000694 effects Effects 0.000 description 12
229910052943 magnesium sulfate Inorganic materials 0.000 description 12
235000019341 magnesium sulphate Nutrition 0.000 description 11
239000000741 silica gel Substances 0.000 description 11
229910002027 silica gel Inorganic materials 0.000 description 11
239000002904 solvent Substances 0.000 description 11
238000012360 testing method Methods 0.000 description 11
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
238000004128 high performance liquid chromatography Methods 0.000 description 10
238000002604 ultrasonography Methods 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
230000001413 cellular effect Effects 0.000 description 9
239000003826 tablet Substances 0.000 description 9
102100032306 Aurora kinase B Human genes 0.000 description 8
101000798306 Homo sapiens Aurora kinase B Proteins 0.000 description 8
239000004480 active ingredient Substances 0.000 description 8
238000001816 cooling Methods 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
238000000021 kinase assay Methods 0.000 description 8
239000007788 liquid Substances 0.000 description 8
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 8
239000002244 precipitate Substances 0.000 description 8
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
235000017557 sodium bicarbonate Nutrition 0.000 description 8
229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
238000004809 thin layer chromatography Methods 0.000 description 8
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 8
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 7
GVRRXASZZAKBMN-UHFFFAOYSA-N 4-chloroquinazoline Chemical class C1=CC=C2C(Cl)=NC=NC2=C1 GVRRXASZZAKBMN-UHFFFAOYSA-N 0.000 description 7
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 7
238000003556 assay Methods 0.000 description 7
239000002585 base Substances 0.000 description 7
239000002775 capsule Substances 0.000 description 7
230000004663 cell proliferation Effects 0.000 description 7
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 7
239000003909 protein kinase inhibitor Substances 0.000 description 7
HXEWMTXDBOQQKO-UHFFFAOYSA-N 4,7-dichloroquinoline Chemical compound ClC1=CC=NC2=CC(Cl)=CC=C21 HXEWMTXDBOQQKO-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
125000006519 CCH3 Chemical group 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 6
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
229910052786 argon Inorganic materials 0.000 description 6
239000012894 fetal calf serum Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
239000002609 medium Substances 0.000 description 6
239000003208 petroleum Substances 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
239000000725 suspension Substances 0.000 description 6
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
JKRSQNBRNIYETC-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)propan-1-ol Chemical compound CN1CCN(CCCO)CC1 JKRSQNBRNIYETC-UHFFFAOYSA-N 0.000 description 5
102100022014 Angiopoietin-1 receptor Human genes 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 5
206010061309 Neoplasm progression Diseases 0.000 description 5
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
239000002253 acid Substances 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 description 5
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
102000027426 receptor tyrosine kinases Human genes 0.000 description 5
108091008598 receptor tyrosine kinases Proteins 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
239000002002 slurry Substances 0.000 description 5
238000003756 stirring Methods 0.000 description 5
230000005751 tumor progression Effects 0.000 description 5
VRVRGVPWCUEOGV-UHFFFAOYSA-N 2-aminothiophenol Chemical class NC1=CC=CC=C1S VRVRGVPWCUEOGV-UHFFFAOYSA-N 0.000 description 4
WJNSNVIQHYHUHX-UHFFFAOYSA-N 2-chloro-n-methylpyrimidin-4-amine Chemical compound CNC1=CC=NC(Cl)=N1 WJNSNVIQHYHUHX-UHFFFAOYSA-N 0.000 description 4
UKLSJMPZHKFSQJ-UHFFFAOYSA-N 4-chloro-n-methylpyrimidin-2-amine Chemical compound CNC1=NC=CC(Cl)=N1 UKLSJMPZHKFSQJ-UHFFFAOYSA-N 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
108010055323 EphB4 Receptor Proteins 0.000 description 4
102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 4
241000282412 Homo Species 0.000 description 4
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
125000002820 allylidene group Chemical group [H]C(=[*])C([H])=C([H])[H] 0.000 description 4
229960004050 aminobenzoic acid Drugs 0.000 description 4
208000007502 anemia Diseases 0.000 description 4
230000033115 angiogenesis Effects 0.000 description 4
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
239000000969 carrier Substances 0.000 description 4
229960004132 diethyl ether Drugs 0.000 description 4
239000012065 filter cake Substances 0.000 description 4
235000019253 formic acid Nutrition 0.000 description 4
238000001802 infusion Methods 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
239000003446 ligand Substances 0.000 description 4
239000007937 lozenge Substances 0.000 description 4
NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 4
230000009456 molecular mechanism Effects 0.000 description 4
230000026731 phosphorylation Effects 0.000 description 4
238000006366 phosphorylation reaction Methods 0.000 description 4
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
230000022983 regulation of cell cycle Effects 0.000 description 4
239000007921 spray Substances 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
239000000375 suspending agent Substances 0.000 description 4
239000012730 sustained-release form Substances 0.000 description 4
239000002562 thickening agent Substances 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
230000005747 tumor angiogenesis Effects 0.000 description 4
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 3
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
FQIRBKKYMJKENC-UHFFFAOYSA-N 2-(4-bromophenyl)-1,3-benzothiazole Chemical compound C1=CC(Br)=CC=C1C1=NC2=CC=CC=C2S1 FQIRBKKYMJKENC-UHFFFAOYSA-N 0.000 description 3
RNEUJJBEBPMWHK-UHFFFAOYSA-N 2-chloro-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound N1C(C)=CC(NC=2N=C(Cl)N=CC=2)=N1 RNEUJJBEBPMWHK-UHFFFAOYSA-N 0.000 description 3
FDUXBBKYPFEDLG-UHFFFAOYSA-N 2-n-[4-(1,3-benzothiazol-2-yl)phenyl]-2-n-methylpyridine-2,4-diamine Chemical compound C=1C=C(C=2SC3=CC=CC=C3N=2)C=CC=1N(C)C1=CC(N)=CC=N1 FDUXBBKYPFEDLG-UHFFFAOYSA-N 0.000 description 3
FJNLCHNQVJVCPY-UHFFFAOYSA-N 2-n-methoxy-2-n-methyl-4-n,6-n-dipropyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(NCCC)=NC(N(C)OC)=N1 FJNLCHNQVJVCPY-UHFFFAOYSA-N 0.000 description 3
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 3
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
PZXJFNOGRSYDFV-UHFFFAOYSA-N 4-[4-(1,3-benzothiazol-2-yl)anilino]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(NC=2C=CC(=CC=2)C=2SC3=CC=CC=C3N=2)=C1 PZXJFNOGRSYDFV-UHFFFAOYSA-N 0.000 description 3
TWTODSLDHCDLDR-UHFFFAOYSA-N 4-chlorothieno[3,2-d]pyrimidine Chemical compound ClC1=NC=NC2=C1SC=C2 TWTODSLDHCDLDR-UHFFFAOYSA-N 0.000 description 3
FYTLHYRDGXRYEY-UHFFFAOYSA-N 5-Methyl-3-pyrazolamine Chemical compound CC=1C=C(N)NN=1 FYTLHYRDGXRYEY-UHFFFAOYSA-N 0.000 description 3
208000030507 AIDS Diseases 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
102000004228 Aurora kinase B Human genes 0.000 description 3
108090000749 Aurora kinase B Proteins 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
206010027476 Metastases Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
239000004698 Polyethylene Substances 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
102000001332 SRC Human genes 0.000 description 3
108060006706 SRC Proteins 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
239000013543 active substance Substances 0.000 description 3
230000006907 apoptotic process Effects 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
230000030833 cell death Effects 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
ODMDLCWSMSFWCW-UHFFFAOYSA-N chembl47875 Chemical compound C1=CC(O)=CC=C1C1=NC2=CC=CC=C2S1 ODMDLCWSMSFWCW-UHFFFAOYSA-N 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000004440 column chromatography Methods 0.000 description 3
239000006071 cream Substances 0.000 description 3
239000013058 crude material Substances 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000002270 dispersing agent Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000003480 eluent Substances 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
238000001640 fractional crystallisation Methods 0.000 description 3
239000000499 gel Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
MIQHHHBYQFQHTK-UHFFFAOYSA-N n-[4-(1,3-benzothiazol-2-yl)phenyl]pyridin-4-amine Chemical compound C=1C=C(C=2SC3=CC=CC=C3N=2)C=CC=1NC1=CC=NC=C1 MIQHHHBYQFQHTK-UHFFFAOYSA-N 0.000 description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
239000006187 pill Substances 0.000 description 3
229920005862 polyol Polymers 0.000 description 3
150000003077 polyols Chemical class 0.000 description 3
229920000137 polyphosphoric acid Polymers 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
238000010992 reflux Methods 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
239000001993 wax Substances 0.000 description 3
CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 3
CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
TUQSVSYUEBNNKQ-UHFFFAOYSA-N 2,4-dichloroquinazoline Chemical class C1=CC=CC2=NC(Cl)=NC(Cl)=C21 TUQSVSYUEBNNKQ-UHFFFAOYSA-N 0.000 description 2
QHTUMQYGZQYEOZ-UHFFFAOYSA-N 2-(4-methylpiperazin-1-yl)ethanol Chemical compound CN1CCN(CCO)CC1 QHTUMQYGZQYEOZ-UHFFFAOYSA-N 0.000 description 2
KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 2
LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 2
DXYYSGDWQCSKKO-UHFFFAOYSA-N 2-methylbenzothiazole Chemical class C1=CC=C2SC(C)=NC2=C1 DXYYSGDWQCSKKO-UHFFFAOYSA-N 0.000 description 2
XBHOUXSGHYZCNH-UHFFFAOYSA-N 2-phenyl-1,3-benzothiazole Chemical group C1=CC=CC=C1C1=NC2=CC=CC=C2S1 XBHOUXSGHYZCNH-UHFFFAOYSA-N 0.000 description 2
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
IQGMRVWUTCYCST-UHFFFAOYSA-N 3-Aminosalicylic acid Chemical compound NC1=CC=CC(C(O)=O)=C1O IQGMRVWUTCYCST-UHFFFAOYSA-N 0.000 description 2
125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 2
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
ZMJQROKRSPSLFH-UHFFFAOYSA-N 3-pyrrolidin-1-ylpropan-1-ol Chemical compound OCCCN1CCCC1 ZMJQROKRSPSLFH-UHFFFAOYSA-N 0.000 description 2
BLBDTBCGPHPIJK-UHFFFAOYSA-N 4-Amino-2-chloropyridine Chemical compound NC1=CC=NC(Cl)=C1 BLBDTBCGPHPIJK-UHFFFAOYSA-N 0.000 description 2
DMBUDLCZXCWIMF-UHFFFAOYSA-N 4-chloro-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline Chemical compound COC1=CC2=C(Cl)N=CN=C2C=C1OCCCN1CCCC1 DMBUDLCZXCWIMF-UHFFFAOYSA-N 0.000 description 2
IEPCUHXQCIATQT-UHFFFAOYSA-N 4-chloro-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline Chemical compound COC1=CC2=C(Cl)N=CN=C2C=C1OCCCN1CCN(C)CC1 IEPCUHXQCIATQT-UHFFFAOYSA-N 0.000 description 2
BXRGTEOKLSVMJU-UHFFFAOYSA-N 4-chloro-6-methoxyquinazolin-7-ol Chemical compound N1=CN=C2C=C(O)C(OC)=CC2=C1Cl BXRGTEOKLSVMJU-UHFFFAOYSA-N 0.000 description 2
HNWMZULUQHJZFN-UHFFFAOYSA-N 4-chloro-7-methoxy-6-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline Chemical compound COC1=CC2=NC=NC(Cl)=C2C=C1OCCCN1CCN(C)CC1 HNWMZULUQHJZFN-UHFFFAOYSA-N 0.000 description 2
ZBOFUZBKDHGCAF-UHFFFAOYSA-N 4-chloro-7-methoxyquinazolin-6-ol Chemical compound C1=NC(Cl)=C2C=C(O)C(OC)=CC2=N1 ZBOFUZBKDHGCAF-UHFFFAOYSA-N 0.000 description 2
PVMNPAUTCMBOMO-UHFFFAOYSA-N 4-chloropyridine Chemical compound ClC1=CC=NC=C1 PVMNPAUTCMBOMO-UHFFFAOYSA-N 0.000 description 2
NNMYRMGMVLMQAY-UHFFFAOYSA-N 4-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=CC=N1 NNMYRMGMVLMQAY-UHFFFAOYSA-N 0.000 description 2
150000005717 4-chloropyrimidines Chemical class 0.000 description 2
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical class ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 2
VMNXKIDUTPOHPO-UHFFFAOYSA-N 6-chloro-1,3-benzothiazol-2-amine Chemical compound C1=C(Cl)C=C2SC(N)=NC2=C1 VMNXKIDUTPOHPO-UHFFFAOYSA-N 0.000 description 2
CJLUXPZQUXVJNF-UHFFFAOYSA-N 6-fluoro-1,3-benzothiazol-2-amine Chemical compound C1=C(F)C=C2SC(N)=NC2=C1 CJLUXPZQUXVJNF-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
229920000742 Cotton Polymers 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
101800003838 Epidermal growth factor Proteins 0.000 description 2
102100037813 Focal adhesion kinase 1 Human genes 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
108010009202 Growth Factor Receptors Proteins 0.000 description 2
102000009465 Growth Factor Receptors Human genes 0.000 description 2
208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
102100033636 Histone H3.2 Human genes 0.000 description 2
108010033040 Histones Proteins 0.000 description 2
208000017604 Hodgkin disease Diseases 0.000 description 2
101000878536 Homo sapiens Focal adhesion kinase 1 Proteins 0.000 description 2
101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 2
101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 2
108060006678 I-kappa-B kinase Proteins 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 2
101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 2
101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 2
208000034189 Sclerosis Diseases 0.000 description 2
102100031206 Serine/threonine-protein kinase N1 Human genes 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
GTZCVFVGUGFEME-UHFFFAOYSA-N aconitic acid Chemical compound OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
208000002399 aphthous stomatitis Diseases 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
239000005441 aurora Substances 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000022131 cell cycle Effects 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000003915 cell function Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
239000003086 colorant Substances 0.000 description 2
239000012043 crude product Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
150000004985 diamines Chemical class 0.000 description 2
WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 2
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000004821 distillation Methods 0.000 description 2
CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
201000002491 encephalomyelitis Diseases 0.000 description 2
229940116977 epidermal growth factor Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
230000005284 excitation Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
239000006260 foam Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
150000002466 imines Chemical class 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
125000001793 isothiazol-3-yl group Chemical group [H]C1=C([H])C(*)=NS1 0.000 description 2
125000004500 isothiazol-4-yl group Chemical group S1N=CC(=C1)* 0.000 description 2
125000004501 isothiazol-5-yl group Chemical group S1N=CC=C1* 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000006210 lotion Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
QXOXUEFXRSIYSW-UHFFFAOYSA-N methyl 3-hydroxy-4-methoxybenzoate Chemical compound COC(=O)C1=CC=C(OC)C(O)=C1 QXOXUEFXRSIYSW-UHFFFAOYSA-N 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
BVWTXUYLKBHMOX-UHFFFAOYSA-N methyl vanillate Chemical compound COC(=O)C1=CC=C(O)C(OC)=C1 BVWTXUYLKBHMOX-UHFFFAOYSA-N 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
210000003928 nasal cavity Anatomy 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
239000002674 ointment Substances 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000006072 paste Substances 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
235000011007 phosphoric acid Nutrition 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
238000002953 preparative HPLC Methods 0.000 description 2
238000012746 preparative thin layer chromatography Methods 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 2
230000009467 reduction Effects 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
201000000306 sarcoidosis Diseases 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
230000003019 stabilising effect Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
QQOWHRYOXYEMTL-UHFFFAOYSA-N triazin-4-amine Chemical compound N=C1C=CN=NN1 QQOWHRYOXYEMTL-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
239000003643 water by type Substances 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
ZGZUKKMFYTUYHA-HNNXBMFYSA-N (2s)-2-amino-3-(4-phenylmethoxyphenyl)propane-1-thiol Chemical compound C1=CC(C[C@@H](CS)N)=CC=C1OCC1=CC=CC=C1 ZGZUKKMFYTUYHA-HNNXBMFYSA-N 0.000 description 1
UVNGEPOWQCFTDI-UHFFFAOYSA-N (6-methoxy-4-oxo-1h-quinazolin-7-yl) acetate Chemical compound N1=CNC(=O)C2=C1C=C(OC(C)=O)C(OC)=C2 UVNGEPOWQCFTDI-UHFFFAOYSA-N 0.000 description 1
SOLQIFINSOHAQD-UHFFFAOYSA-N (7-methoxy-4-oxo-1h-quinazolin-6-yl) acetate Chemical compound N1C=NC(=O)C2=C1C=C(OC)C(OC(C)=O)=C2 SOLQIFINSOHAQD-UHFFFAOYSA-N 0.000 description 1
239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 description 1
WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
OWQPOVKKUWUEKE-UHFFFAOYSA-N 1,2,3-benzotriazine Chemical compound N1=NN=CC2=CC=CC=C21 OWQPOVKKUWUEKE-UHFFFAOYSA-N 0.000 description 1
125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 description 1
125000001506 1,2,3-triazol-5-yl group Chemical group [H]N1N=NC([H])=C1[*] 0.000 description 1
125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 description 1
125000004515 1,2,4-thiadiazol-3-yl group Chemical group S1N=C(N=C1)* 0.000 description 1
125000004516 1,2,4-thiadiazol-5-yl group Chemical group S1N=CN=C1* 0.000 description 1
125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 1
125000001414 1,2,4-triazol-5-yl group Chemical group [H]N1N=C([H])N=C1[*] 0.000 description 1
125000004507 1,2,5-oxadiazol-3-yl group Chemical group O1N=C(C=N1)* 0.000 description 1
125000004508 1,2,5-oxadiazol-4-yl group Chemical group O1N=CC(=N1)* 0.000 description 1
125000004518 1,2,5-thiadiazol-3-yl group Chemical group S1N=C(C=N1)* 0.000 description 1
125000004519 1,2,5-thiadiazol-4-yl group Chemical group S1N=CC(=N1)* 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
WRXNBPPHOGBNCG-UHFFFAOYSA-N 1-(7h-purin-2-yl)-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=C2NC=NC2=NC(C2C3=CC=CC=C3CCN2)=N1 WRXNBPPHOGBNCG-UHFFFAOYSA-N 0.000 description 1
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical class NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 1
AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 1
BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
GMLOBPPUIRPVHD-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-4-[(4,6-dimethylpyrimidin-2-yl)amino]phenol Chemical compound CC1=CC(C)=NC(NC=2C=C(C(O)=CC=2)C=2SC3=CC=CC=C3N=2)=N1 GMLOBPPUIRPVHD-UHFFFAOYSA-N 0.000 description 1
QPCBGNWSEYXBQL-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C1=CC=C2SC(C=3C(O)=CC=C(C=3)NC=3N=CN=C4C=C(C(=CC4=3)OC)OC)=NC2=C1 QPCBGNWSEYXBQL-UHFFFAOYSA-N 0.000 description 1
ANARGLWUULOVMT-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-5-[(4,6-dimethylpyrimidin-2-yl)amino]phenol Chemical compound CC1=CC(C)=NC(NC=2C=C(O)C(C=3SC4=CC=CC=C4N=3)=CC=2)=N1 ANARGLWUULOVMT-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
YFLDSBCDDHPQSM-UHFFFAOYSA-N 2-[5-[6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-yl]oxypyridin-2-yl]-1,3-benzothiazole Chemical compound COC1=CC2=C(OC=3C=NC(=CC=3)C=3SC4=CC=CC=C4N=3)N=CN=C2C=C1OCCCN1CCCC1 YFLDSBCDDHPQSM-UHFFFAOYSA-N 0.000 description 1
MVTRQRSNYWDWMY-UHFFFAOYSA-N 2-amino-4-(trifluoromethyl)benzenethiol Chemical compound NC1=CC(C(F)(F)F)=CC=C1S MVTRQRSNYWDWMY-UHFFFAOYSA-N 0.000 description 1
NGIRMPARLVGMPX-UHFFFAOYSA-N 2-amino-4-chlorobenzenethiol Chemical compound NC1=CC(Cl)=CC=C1S NGIRMPARLVGMPX-UHFFFAOYSA-N 0.000 description 1
ULJXIGMLEZGSBM-UHFFFAOYSA-N 2-amino-5-(1,3-benzothiazol-2-yl)phenol Chemical compound C1=C(O)C(N)=CC=C1C1=NC2=CC=CC=C2S1 ULJXIGMLEZGSBM-UHFFFAOYSA-N 0.000 description 1
VPBFNGJZAYKJJX-UHFFFAOYSA-N 2-amino-6-(1,3-benzothiazol-2-yl)phenol Chemical compound NC1=CC=CC(C=2SC3=CC=CC=C3N=2)=C1O VPBFNGJZAYKJJX-UHFFFAOYSA-N 0.000 description 1
UHGULLIUJBCTEF-UHFFFAOYSA-N 2-aminobenzothiazole Chemical class C1=CC=C2SC(N)=NC2=C1 UHGULLIUJBCTEF-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
DLSDRFQCEQEWGN-UHFFFAOYSA-N 2-chloro-4-(4-methylpiperazin-1-yl)pyrimidine Chemical compound C1CN(C)CCN1C1=CC=NC(Cl)=N1 DLSDRFQCEQEWGN-UHFFFAOYSA-N 0.000 description 1
UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
150000005716 2-chloropyrimidines Chemical class 0.000 description 1
AFVMHFKOSRIYDL-UHFFFAOYSA-N 2-fluoro-4-(6-fluoro-1,3-benzothiazol-2-yl)aniline Chemical compound C1=C(F)C(N)=CC=C1C1=NC2=CC=C(F)C=C2S1 AFVMHFKOSRIYDL-UHFFFAOYSA-N 0.000 description 1
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
SHLRSTFQNUVOIX-UHFFFAOYSA-N 2-n-[3-(1,3-benzothiazol-2-yl)phenyl]-4-n-methylpyrimidine-2,4-diamine Chemical compound CNC1=CC=NC(NC=2C=C(C=CC=2)C=2SC3=CC=CC=C3N=2)=N1 SHLRSTFQNUVOIX-UHFFFAOYSA-N 0.000 description 1
HSMLVQPVLGLUCI-UHFFFAOYSA-N 2-n-[4-(1,3-benzothiazol-2-yl)-3-methoxyphenyl]-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound C=1C=C(C=2SC3=CC=CC=C3N=2)C(OC)=CC=1NC(N=1)=NC=CC=1NC=1C=C(C)NN=1 HSMLVQPVLGLUCI-UHFFFAOYSA-N 0.000 description 1
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
CJGGKSPGRJHZNP-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyrazine Chemical compound C1=CN=C2NN=NC2=N1 CJGGKSPGRJHZNP-UHFFFAOYSA-N 0.000 description 1
CBHTTYDJRXOHHL-UHFFFAOYSA-N 2h-triazolo[4,5-c]pyridazine Chemical group N1=NC=CC2=C1N=NN2 CBHTTYDJRXOHHL-UHFFFAOYSA-N 0.000 description 1
LIZOFKWBNVAHPD-UHFFFAOYSA-N 2h-triazolo[4,5-d]triazine Chemical compound C1=NN=NC2=C1NN=N2 LIZOFKWBNVAHPD-UHFFFAOYSA-N 0.000 description 1
GDZBKIWVWVAQEK-UHFFFAOYSA-N 3-(1,3-benzothiazol-2-yl)-4-chloroaniline Chemical compound NC1=CC=C(Cl)C(C=2SC3=CC=CC=C3N=2)=C1 GDZBKIWVWVAQEK-UHFFFAOYSA-N 0.000 description 1
MKMRZZJJDIBAJF-UHFFFAOYSA-N 3-(1,3-benzothiazol-2-yl)aniline Chemical compound NC1=CC=CC(C=2SC3=CC=CC=C3N=2)=C1 MKMRZZJJDIBAJF-UHFFFAOYSA-N 0.000 description 1
AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 1
DMGFVJVLVZOSOE-UHFFFAOYSA-N 3-amino-4-chlorobenzoic acid Chemical compound NC1=CC(C(O)=O)=CC=C1Cl DMGFVJVLVZOSOE-UHFFFAOYSA-N 0.000 description 1
XKFIFYROMAAUDL-UHFFFAOYSA-N 3-amino-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C=C1N XKFIFYROMAAUDL-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
IUSDEKNMCOUBEE-UHFFFAOYSA-N 3-fluoro-4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(F)=C1 IUSDEKNMCOUBEE-UHFFFAOYSA-N 0.000 description 1
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
150000005167 3-hydroxybenzoic acids Chemical class 0.000 description 1
VZKSLWJLGAGPIU-UHFFFAOYSA-N 3-morpholin-4-ylpropan-1-ol Chemical compound OCCCN1CCOCC1 VZKSLWJLGAGPIU-UHFFFAOYSA-N 0.000 description 1
102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 1
125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
ROUZEIBKLXOKPP-UHFFFAOYSA-N 4-(1,3-benzothiazol-2-yl)-2-(trifluoromethoxy)aniline Chemical compound C1=C(OC(F)(F)F)C(N)=CC=C1C1=NC2=CC=CC=C2S1 ROUZEIBKLXOKPP-UHFFFAOYSA-N 0.000 description 1
YPMSJWNNIBRQDS-UHFFFAOYSA-N 4-(1,3-benzothiazol-2-yl)-2-fluoroaniline Chemical compound C1=C(F)C(N)=CC=C1C1=NC2=CC=CC=C2S1 YPMSJWNNIBRQDS-UHFFFAOYSA-N 0.000 description 1
BKTFPKDWBGTAPI-UHFFFAOYSA-N 4-(1,3-benzothiazol-2-yl)-2-fluorophenol Chemical compound C1=C(F)C(O)=CC=C1C1=NC2=CC=CC=C2S1 BKTFPKDWBGTAPI-UHFFFAOYSA-N 0.000 description 1
IDBCUMFOZBUJCL-UHFFFAOYSA-N 4-(1,3-benzothiazol-2-yl)-2-methylaniline Chemical compound C1=C(N)C(C)=CC(C=2SC3=CC=CC=C3N=2)=C1 IDBCUMFOZBUJCL-UHFFFAOYSA-N 0.000 description 1
DRFGKQLPMWOHTF-UHFFFAOYSA-N 4-(1,3-benzothiazol-2-yl)-3-chloroaniline Chemical compound ClC1=CC(N)=CC=C1C1=NC2=CC=CC=C2S1 DRFGKQLPMWOHTF-UHFFFAOYSA-N 0.000 description 1
BDEYHVZNXILQCB-UHFFFAOYSA-N 4-(1,3-benzothiazol-2-yl)-3-fluoroaniline Chemical compound FC1=CC(N)=CC=C1C1=NC2=CC=CC=C2S1 BDEYHVZNXILQCB-UHFFFAOYSA-N 0.000 description 1
MNTUFMJRNAMDSS-UHFFFAOYSA-N 4-(1,3-benzothiazol-2-yl)-3-methoxy-n-methylaniline Chemical compound COC1=CC(NC)=CC=C1C1=NC2=CC=CC=C2S1 MNTUFMJRNAMDSS-UHFFFAOYSA-N 0.000 description 1
NELUBVQBGYHASV-UHFFFAOYSA-N 4-(1,3-benzothiazol-2-yl)-3-methoxyaniline Chemical compound COC1=CC(N)=CC=C1C1=NC2=CC=CC=C2S1 NELUBVQBGYHASV-UHFFFAOYSA-N 0.000 description 1
OLBUFUDLVSWXBF-UHFFFAOYSA-N 4-(1,3-benzothiazol-2-yl)-3-methylaniline Chemical compound CC1=CC(N)=CC=C1C1=NC2=CC=CC=C2S1 OLBUFUDLVSWXBF-UHFFFAOYSA-N 0.000 description 1
DYRKGSIUMTZZQV-UHFFFAOYSA-N 4-(5-chloro-1,3-benzothiazol-2-yl)aniline Chemical compound C1=CC(N)=CC=C1C1=NC2=CC(Cl)=CC=C2S1 DYRKGSIUMTZZQV-UHFFFAOYSA-N 0.000 description 1
WZRRXNJALRCBNH-UHFFFAOYSA-N 4-(6-bromo-1,3-benzothiazol-2-yl)aniline Chemical compound C1=CC(N)=CC=C1C1=NC2=CC=C(Br)C=C2S1 WZRRXNJALRCBNH-UHFFFAOYSA-N 0.000 description 1
WDHOPXCHRDCMEK-UHFFFAOYSA-N 4-(6-chloro-1,3-benzothiazol-2-yl)-2-fluoroaniline Chemical compound C1=C(F)C(N)=CC=C1C1=NC2=CC=C(Cl)C=C2S1 WDHOPXCHRDCMEK-UHFFFAOYSA-N 0.000 description 1
BZZOPZVSATZUNJ-UHFFFAOYSA-N 4-(6-chloro-1,3-benzothiazol-2-yl)aniline Chemical compound C1=CC(N)=CC=C1C1=NC2=CC=C(Cl)C=C2S1 BZZOPZVSATZUNJ-UHFFFAOYSA-N 0.000 description 1
FIHRCVGMRDXVHA-UHFFFAOYSA-N 4-(6-fluoro-1,3-benzothiazol-2-yl)aniline Chemical compound C1=CC(N)=CC=C1C1=NC2=CC=C(F)C=C2S1 FIHRCVGMRDXVHA-UHFFFAOYSA-N 0.000 description 1
BPAYXCPRXZOLEN-UHFFFAOYSA-N 4-[4-(1,3-benzothiazol-2-yl)phenyl]-2-methylimino-1,3-dihydropyridin-4-amine Chemical compound S1C(=NC2=C1C=CC=C2)C2=CC=C(C=C2)C2(CC(=NC=C2)NC)N BPAYXCPRXZOLEN-UHFFFAOYSA-N 0.000 description 1
YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
LMPNKXKRMDWQSZ-UHFFFAOYSA-N 4-[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]aniline Chemical compound C1=CC(N)=CC=C1C1=NC2=CC(C(F)(F)F)=CC=C2S1 LMPNKXKRMDWQSZ-UHFFFAOYSA-N 0.000 description 1
AFDQPMMSGGIXSU-UHFFFAOYSA-N 4-[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]aniline Chemical compound C1=CC(N)=CC=C1C1=NC2=CC=C(OC(F)(F)F)C=C2S1 AFDQPMMSGGIXSU-UHFFFAOYSA-N 0.000 description 1
MBDUKNCPOPMRJQ-UHFFFAOYSA-N 4-amino-2-chlorobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C(Cl)=C1 MBDUKNCPOPMRJQ-UHFFFAOYSA-N 0.000 description 1
QHERSCUZBKDVOC-UHFFFAOYSA-N 4-amino-2-fluorobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C(F)=C1 QHERSCUZBKDVOC-UHFFFAOYSA-N 0.000 description 1
OLJXRTRRJSMURJ-UHFFFAOYSA-N 4-amino-2-methoxybenzoic acid Chemical compound COC1=CC(N)=CC=C1C(O)=O OLJXRTRRJSMURJ-UHFFFAOYSA-N 0.000 description 1
XRSQZFJLEPBPOZ-UHFFFAOYSA-N 4-amino-2-methylbenzoic acid Chemical compound CC1=CC(N)=CC=C1C(O)=O XRSQZFJLEPBPOZ-UHFFFAOYSA-N 0.000 description 1
IXJFWBNYFTWBOR-UHFFFAOYSA-N 4-amino-3-(trifluoromethoxy)benzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1OC(F)(F)F IXJFWBNYFTWBOR-UHFFFAOYSA-N 0.000 description 1
JSKXHTHMCCDEGD-UHFFFAOYSA-N 4-amino-3-fluorobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1F JSKXHTHMCCDEGD-UHFFFAOYSA-N 0.000 description 1
NFPYJDZQOKCYIE-UHFFFAOYSA-N 4-amino-3-hydroxybenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1O NFPYJDZQOKCYIE-UHFFFAOYSA-N 0.000 description 1
JNFGLYJROFAOQP-UHFFFAOYSA-N 4-amino-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1N JNFGLYJROFAOQP-UHFFFAOYSA-N 0.000 description 1
NHFKECPTBZZFBC-UHFFFAOYSA-N 4-amino-3-methylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1N NHFKECPTBZZFBC-UHFFFAOYSA-N 0.000 description 1
150000005416 4-aminobenzoic acids Chemical class 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
TUXYZHVUPGXXQG-UHFFFAOYSA-N 4-bromobenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C=C1 TUXYZHVUPGXXQG-UHFFFAOYSA-N 0.000 description 1
DBPKMSBWOKAKLA-UHFFFAOYSA-N 4-chloropyrimidine Chemical compound ClC1=CC=NC=N1 DBPKMSBWOKAKLA-UHFFFAOYSA-N 0.000 description 1
229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
PGQKSCKLIPLUPQ-UHFFFAOYSA-N 4-n-[3-(1,3-benzothiazol-2-yl)phenyl]-2-n-methylpyrimidine-2,4-diamine Chemical compound CNC1=NC=CC(NC=2C=C(C=CC=2)C=2SC3=CC=CC=C3N=2)=N1 PGQKSCKLIPLUPQ-UHFFFAOYSA-N 0.000 description 1
MVXAWROAJALYHX-UHFFFAOYSA-N 4-n-[4-(1,3-benzothiazol-2-yl)phenyl]-2-n-(5-methyl-1h-pyrazol-3-yl)pyridine-2,4-diamine Chemical compound N1C(C)=CC(NC=2N=CC=C(NC=3C=CC(=CC=3)C=3SC4=CC=CC=C4N=3)C=2)=N1 MVXAWROAJALYHX-UHFFFAOYSA-N 0.000 description 1
IXMITROVYBNKPV-UHFFFAOYSA-N 4-n-[4-(1,3-benzothiazol-2-yl)phenyl]-2-n-methylpyrimidine-2,4-diamine Chemical compound CNC1=NC=CC(NC=2C=CC(=CC=2)C=2SC3=CC=CC=C3N=2)=N1 IXMITROVYBNKPV-UHFFFAOYSA-N 0.000 description 1
SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 1
NMILGIZTAZXMTM-UHFFFAOYSA-N 4-propylmorpholine Chemical compound CCCN1CCOCC1 NMILGIZTAZXMTM-UHFFFAOYSA-N 0.000 description 1
AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
IRRAMJXBKRGJME-UHFFFAOYSA-N 5-(1,3-benzothiazol-2-yl)-2-chloroaniline Chemical compound C1=C(Cl)C(N)=CC(C=2SC3=CC=CC=C3N=2)=C1 IRRAMJXBKRGJME-UHFFFAOYSA-N 0.000 description 1
RLYKSASURFRWIY-UHFFFAOYSA-N 5-(1,3-benzothiazol-2-yl)-2-methylaniline Chemical compound C1=C(N)C(C)=CC=C1C1=NC2=CC=CC=C2S1 RLYKSASURFRWIY-UHFFFAOYSA-N 0.000 description 1
GVCFFVPEOLCYNN-UHFFFAOYSA-N 5-amino-2-chlorobenzoic acid Chemical compound NC1=CC=C(Cl)C(C(O)=O)=C1 GVCFFVPEOLCYNN-UHFFFAOYSA-N 0.000 description 1
RXQZLSRIOOYKLF-UHFFFAOYSA-N 5H-pyrazolo[4,3-d]triazine Chemical compound N1=NN=C2C=NNC2=C1 RXQZLSRIOOYKLF-UHFFFAOYSA-N 0.000 description 1
MJQSRSOTRPMVKB-UHFFFAOYSA-N 5h-imidazo[4,5-c]pyridazine Chemical compound C1=NNC2=NC=NC2=C1 MJQSRSOTRPMVKB-UHFFFAOYSA-N 0.000 description 1
XZLIYCQRASOFQM-UHFFFAOYSA-N 5h-imidazo[4,5-d]triazine Chemical compound N1=NC=C2NC=NC2=N1 XZLIYCQRASOFQM-UHFFFAOYSA-N 0.000 description 1
VZEBSJIOUMDNLY-UHFFFAOYSA-N 6-bromo-1,3-benzothiazol-2-amine Chemical compound C1=C(Br)C=C2SC(N)=NC2=C1 VZEBSJIOUMDNLY-UHFFFAOYSA-N 0.000 description 1
OKZIRNNFVQCDSA-UHFFFAOYSA-N 6-hydroxy-7-methoxy-1h-quinazolin-4-one Chemical compound C1=NC(O)=C2C=C(O)C(OC)=CC2=N1 OKZIRNNFVQCDSA-UHFFFAOYSA-N 0.000 description 1
KZHGPDSVHSDCMX-UHFFFAOYSA-N 6-methoxy-1,3-benzothiazol-2-amine Chemical compound COC1=CC=C2N=C(N)SC2=C1 KZHGPDSVHSDCMX-UHFFFAOYSA-N 0.000 description 1
IUQPNHYCLQPISC-UHFFFAOYSA-N 6-methoxy-1h-quinazolin-2-one Chemical compound N1C(=O)N=CC2=CC(OC)=CC=C21 IUQPNHYCLQPISC-UHFFFAOYSA-N 0.000 description 1
ZHLRYPLSYOYNQM-UHFFFAOYSA-N 7-hydroxy-6-methoxy-1h-quinazolin-4-one Chemical compound N1=CN=C2C=C(O)C(OC)=CC2=C1O ZHLRYPLSYOYNQM-UHFFFAOYSA-N 0.000 description 1
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000026872 Addison Disease Diseases 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
101001077245 Aplysia californica Spermatozoon-associated protein kinase Proteins 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
208000006373 Bell palsy Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
102000043139 CK2 family Human genes 0.000 description 1
108091054872 CK2 family Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000002691 Choroiditis Diseases 0.000 description 1
206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
102100036329 Cyclin-dependent kinase 3 Human genes 0.000 description 1
102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 1
102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
201000003066 Diffuse Scleroderma Diseases 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
208000001708 Dupuytren contracture Diseases 0.000 description 1
101150076616 EPHA2 gene Proteins 0.000 description 1
101150097734 EPHB2 gene Proteins 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
102100030011 Endoribonuclease Human genes 0.000 description 1
101710199605 Endoribonuclease Proteins 0.000 description 1
208000004232 Enteritis Diseases 0.000 description 1
108010055211 EphA1 Receptor Proteins 0.000 description 1
101150078651 Epha4 gene Proteins 0.000 description 1
102100030322 Ephrin type-A receptor 1 Human genes 0.000 description 1
102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
102100021616 Ephrin type-A receptor 4 Human genes 0.000 description 1
102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 1
102100031982 Ephrin type-B receptor 3 Human genes 0.000 description 1
241000402754 Erythranthe moschata Species 0.000 description 1
206010016952 Food poisoning Diseases 0.000 description 1
208000019331 Foodborne disease Diseases 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
230000010190 G1 phase Effects 0.000 description 1
230000004668 G2/M phase Effects 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
101000606500 Gallus gallus Inactive tyrosine-protein kinase 7 Proteins 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 1
108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
208000024869 Goodpasture syndrome Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
208000001204 Hashimoto Disease Diseases 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
108091006054 His-tagged proteins Proteins 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
101000715946 Homo sapiens Cyclin-dependent kinase 3 Proteins 0.000 description 1
101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 1
101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
101001064458 Homo sapiens Ephrin type-B receptor 3 Proteins 0.000 description 1
101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 description 1
101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 description 1
101000762967 Homo sapiens Lymphokine-activated killer T-cell-originated protein kinase Proteins 0.000 description 1
101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 1
101000970023 Homo sapiens NUAK family SNF1-like kinase 1 Proteins 0.000 description 1
101000610537 Homo sapiens Prokineticin-1 Proteins 0.000 description 1
101000606502 Homo sapiens Protein-tyrosine kinase 6 Proteins 0.000 description 1
101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 1
101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
101000798007 Homo sapiens RAC-gamma serine/threonine-protein kinase Proteins 0.000 description 1
101000669921 Homo sapiens Rho-associated protein kinase 2 Proteins 0.000 description 1
101000701393 Homo sapiens Serine/threonine-protein kinase 26 Proteins 0.000 description 1
101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
101001026870 Homo sapiens Serine/threonine-protein kinase D1 Proteins 0.000 description 1
101001129076 Homo sapiens Serine/threonine-protein kinase N1 Proteins 0.000 description 1
101000601441 Homo sapiens Serine/threonine-protein kinase Nek2 Proteins 0.000 description 1
101000588540 Homo sapiens Serine/threonine-protein kinase Nek6 Proteins 0.000 description 1
101000987310 Homo sapiens Serine/threonine-protein kinase PAK 2 Proteins 0.000 description 1
101000987297 Homo sapiens Serine/threonine-protein kinase PAK 4 Proteins 0.000 description 1
101000729945 Homo sapiens Serine/threonine-protein kinase PLK2 Proteins 0.000 description 1
101000864800 Homo sapiens Serine/threonine-protein kinase Sgk1 Proteins 0.000 description 1
101000864831 Homo sapiens Serine/threonine-protein kinase Sgk3 Proteins 0.000 description 1
101000649929 Homo sapiens Serine/threonine-protein kinase VRK1 Proteins 0.000 description 1
101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 1
101001001648 Homo sapiens Serine/threonine-protein kinase pim-2 Proteins 0.000 description 1
101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
101000922131 Homo sapiens Tyrosine-protein kinase CSK Proteins 0.000 description 1
101001050476 Homo sapiens Tyrosine-protein kinase ITK/TSK Proteins 0.000 description 1
101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
101000604583 Homo sapiens Tyrosine-protein kinase SYK Proteins 0.000 description 1
101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 1
101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 description 1
101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
206010058359 Hypogonadism Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061217 Infestation Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 description 1
102100021857 Inhibitor of nuclear factor kappa-B kinase subunit epsilon Human genes 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
238000000023 Kugelrohr distillation Methods 0.000 description 1
239000005517 L01XE01 - Imatinib Substances 0.000 description 1
239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
241000222722 Leishmania <genus> Species 0.000 description 1
102100026753 Lymphokine-activated killer T-cell-originated protein kinase Human genes 0.000 description 1
101150078127 MUSK gene Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010025476 Malabsorption Diseases 0.000 description 1
208000004155 Malabsorption Syndromes Diseases 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 1
102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
102100038168 Muscle, skeletal receptor tyrosine-protein kinase Human genes 0.000 description 1
208000003926 Myelitis Diseases 0.000 description 1
206010028665 Myxoedema Diseases 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
102100021732 NUAK family SNF1-like kinase 1 Human genes 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
101000971435 Oryctolagus cuniculus Protein kinase C gamma type Proteins 0.000 description 1
101700056750 PAK1 Proteins 0.000 description 1
108091008606 PDGF receptors Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
201000011152 Pemphigus Diseases 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
208000031845 Pernicious anaemia Diseases 0.000 description 1
101710184482 Peroxisomal carnitine O-octanoyltransferase Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
241000233872 Pneumocystis carinii Species 0.000 description 1
206010036030 Polyarthritis Diseases 0.000 description 1
229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010078137 Protein Kinase C-epsilon Proteins 0.000 description 1
102000014458 Protein Kinase C-epsilon Human genes 0.000 description 1
108010015499 Protein Kinase C-theta Proteins 0.000 description 1
102000001892 Protein Kinase C-theta Human genes 0.000 description 1
102100024924 Protein kinase C alpha type Human genes 0.000 description 1
101710109947 Protein kinase C alpha type Proteins 0.000 description 1
102100037314 Protein kinase C gamma type Human genes 0.000 description 1
101710144823 Protein kinase C gamma type Proteins 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
102100039810 Protein-tyrosine kinase 6 Human genes 0.000 description 1
102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010037549 Purpura Diseases 0.000 description 1
241001672981 Purpura Species 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 1
102100032314 RAC-gamma serine/threonine-protein kinase Human genes 0.000 description 1
102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
102100039314 Rho-associated protein kinase 2 Human genes 0.000 description 1
102100024908 Ribosomal protein S6 kinase beta-1 Human genes 0.000 description 1
101710108924 Ribosomal protein S6 kinase beta-1 Proteins 0.000 description 1
FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
230000018199 S phase Effects 0.000 description 1
108091006629 SLC13A2 Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
206010039705 Scleritis Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
102100026758 Serine/threonine-protein kinase 16 Human genes 0.000 description 1
102100030617 Serine/threonine-protein kinase 26 Human genes 0.000 description 1
102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
102100037310 Serine/threonine-protein kinase D1 Human genes 0.000 description 1
102100037703 Serine/threonine-protein kinase Nek2 Human genes 0.000 description 1
102100031401 Serine/threonine-protein kinase Nek6 Human genes 0.000 description 1
102100027939 Serine/threonine-protein kinase PAK 2 Human genes 0.000 description 1
102100027940 Serine/threonine-protein kinase PAK 4 Human genes 0.000 description 1
102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 1
102100031462 Serine/threonine-protein kinase PLK2 Human genes 0.000 description 1
102100030267 Serine/threonine-protein kinase PLK4 Human genes 0.000 description 1
102100030070 Serine/threonine-protein kinase Sgk1 Human genes 0.000 description 1
102100030071 Serine/threonine-protein kinase Sgk3 Human genes 0.000 description 1
102100028235 Serine/threonine-protein kinase VRK1 Human genes 0.000 description 1
102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 1
102100036120 Serine/threonine-protein kinase pim-2 Human genes 0.000 description 1
208000032384 Severe immune-mediated enteropathy Diseases 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
101150108263 Stk16 gene Proteins 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
206010061373 Sudden Hearing Loss Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
101001045447 Synechocystis sp. (strain PCC 6803 / Kazusa) Sensor histidine kinase Hik2 Proteins 0.000 description 1
201000009594 Systemic Scleroderma Diseases 0.000 description 1
206010042953 Systemic sclerosis Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
101150077668 TSF1 gene Proteins 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
102100029355 Testis-specific serine/threonine-protein kinase 2 Human genes 0.000 description 1
101710116854 Testis-specific serine/threonine-protein kinase 2 Proteins 0.000 description 1
206010070517 Type 2 lepra reaction Diseases 0.000 description 1
102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
102100031167 Tyrosine-protein kinase CSK Human genes 0.000 description 1
102100023345 Tyrosine-protein kinase ITK/TSK Human genes 0.000 description 1
102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
102100038183 Tyrosine-protein kinase SYK Human genes 0.000 description 1
102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
239000004904 UV filter Substances 0.000 description 1
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
241000700605 Viruses Species 0.000 description 1
206010047642 Vitiligo Diseases 0.000 description 1
102100023037 Wee1-like protein kinase Human genes 0.000 description 1
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
FKAWLXNLHHIHLA-YCBIHMBMSA-N [(2r,3r,5r,7r,8s,9s)-2-[(1s,3s,4s,5r,6r,7e,9e,11e,13z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraenyl]-9-[(e)-3-[2-[(2s)-4-[[(2s,3s,4s)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoyl]amino]butan-2-yl]-1,3-oxazol-4 Chemical compound O1C([C@@H](C)CCNC(=O)[C@@H](O)[C@@H](O)[C@H](COC)N(C)C)=NC(\C=C\C[C@H]2[C@H]([C@H](O)C[C@]3(O2)C([C@@H](OP(O)(O)=O)[C@@H]([C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C(\C)=C\C=C\C(\C)=C/C#N)OC)O3)(C)C)C)=C1 FKAWLXNLHHIHLA-YCBIHMBMSA-N 0.000 description 1
MBKUOPNOYAVQPZ-UHFFFAOYSA-N [1,2]thiazolo[3,4-b]pyrazine Chemical compound N1=CC=NC2=CSN=C21 MBKUOPNOYAVQPZ-UHFFFAOYSA-N 0.000 description 1
MHIJLPSBYNTMDQ-UHFFFAOYSA-N [1,2]thiazolo[4,3-d]pyrimidine Chemical compound C1=NC=NC2=CSN=C21 MHIJLPSBYNTMDQ-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229940091179 aconitate Drugs 0.000 description 1
229940091181 aconitic acid Drugs 0.000 description 1
208000037855 acute anterior uveitis Diseases 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
229910001413 alkali metal ion Inorganic materials 0.000 description 1
229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
208000004631 alopecia areata Diseases 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
150000005415 aminobenzoic acids Chemical class 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
235000021311 artificial sweeteners Nutrition 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
230000001977 ataxic effect Effects 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
208000001974 autoimmune enteropathy Diseases 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004238 benzotriazol-4-yl group Chemical group [H]N1N=NC2=C(*)C([H])=C([H])C([H])=C12 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000018486 cell cycle phase Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000011748 cell maturation Effects 0.000 description 1
230000010001 cellular homeostasis Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
PJHQPFRPACFPPM-UHFFFAOYSA-N chembl113822 Chemical compound OC1=CC(N)=CC=C1C1=NC2=CC=CC=C2S1 PJHQPFRPACFPPM-UHFFFAOYSA-N 0.000 description 1
UBRCBHVOYDSGKZ-UHFFFAOYSA-N chembl1422046 Chemical compound NC1=CC=C(O)C(C=2SC3=CC=CC=C3N=2)=C1 UBRCBHVOYDSGKZ-UHFFFAOYSA-N 0.000 description 1
OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 1
MPXQJBIEYPHEBG-UHFFFAOYSA-N chembl473351 Chemical compound C1=CC=C2SC(C3=CC=C(C=C3O)NC=3N=CN=C4C=C(C(=CC4=3)OC)OC)=NC2=C1 MPXQJBIEYPHEBG-UHFFFAOYSA-N 0.000 description 1
239000007810 chemical reaction solvent Substances 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
229940114081 cinnamate Drugs 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000000306 component Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
201000003278 cryoglobulinemia Diseases 0.000 description 1
208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
201000010064 diabetes insipidus Diseases 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
229950005627 embonate Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
229950011470 enantate Drugs 0.000 description 1
206010014801 endophthalmitis Diseases 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
229940052303 ethers for general anesthesia Drugs 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
229940080856 gleevec Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000009643 growth defect Effects 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
210000004209 hair Anatomy 0.000 description 1
210000003128 head Anatomy 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000010370 hearing loss Effects 0.000 description 1
231100000888 hearing loss Toxicity 0.000 description 1
208000016354 hearing loss disease Diseases 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
201000001505 hemoglobinuria Diseases 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
239000005457 ice water Substances 0.000 description 1
YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
230000008938 immune dysregulation Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
201000006747 infectious mononucleosis Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000008011 inorganic excipient Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000009830 intercalation Methods 0.000 description 1
230000002687 intercalation Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
229960004903 invert sugar Drugs 0.000 description 1
229940084651 iressa Drugs 0.000 description 1
201000004614 iritis Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000008263 liquid aerosol Substances 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
229960004963 mesalazine Drugs 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
KVKBPICSIFDGGR-UHFFFAOYSA-N methyl 2-amino-4-hydroxy-5-methoxybenzoate Chemical compound COC(=O)C1=CC(OC)=C(O)C=C1N KVKBPICSIFDGGR-UHFFFAOYSA-N 0.000 description 1
PZCOPZZPGYOVIU-UHFFFAOYSA-N methyl 2-amino-5-hydroxy-4-methoxybenzoate Chemical compound COC(=O)C1=CC(O)=C(OC)C=C1N PZCOPZZPGYOVIU-UHFFFAOYSA-N 0.000 description 1
PYFSLJVSCGXYAJ-UHFFFAOYSA-N methyl 2-hydroxy-4-[[3-(2-hydroxyphenyl)phenyl]sulfonylamino]benzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=CC=CC(C=2C(=CC=CC=2)O)=C1 PYFSLJVSCGXYAJ-UHFFFAOYSA-N 0.000 description 1
FPGZHXRPIFVQOL-UHFFFAOYSA-N methyl 3-methoxy-4-phenylmethoxybenzoate Chemical compound COC1=CC(C(=O)OC)=CC=C1OCC1=CC=CC=C1 FPGZHXRPIFVQOL-UHFFFAOYSA-N 0.000 description 1
QSRRZKPKHJHIRB-UHFFFAOYSA-N methyl 4-[(2,5-dichloro-4-methylthiophen-3-yl)sulfonylamino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=C(Cl)SC(Cl)=C1C QSRRZKPKHJHIRB-UHFFFAOYSA-N 0.000 description 1
YGDGZDGRCWHDOU-UHFFFAOYSA-N methyl 4-[[5-chloro-4-(2-hydroxyphenyl)thiophen-2-yl]sulfonylamino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=CC(C=2C(=CC=CC=2)O)=C(Cl)S1 YGDGZDGRCWHDOU-UHFFFAOYSA-N 0.000 description 1
SHQBNKDRVJNGDX-UHFFFAOYSA-N methyl 4-methoxy-2-nitro-5-phenylmethoxybenzoate Chemical compound C1=C([N+]([O-])=O)C(C(=O)OC)=CC(OCC=2C=CC=CC=2)=C1OC SHQBNKDRVJNGDX-UHFFFAOYSA-N 0.000 description 1
JCAPCXSPAUTEJF-UHFFFAOYSA-N methyl 4-methoxy-3-phenylmethoxybenzoate Chemical compound COC(=O)C1=CC=C(OC)C(OCC=2C=CC=CC=2)=C1 JCAPCXSPAUTEJF-UHFFFAOYSA-N 0.000 description 1
GUOGVJFNFLXSLK-UHFFFAOYSA-N methyl 5-methoxy-2-nitro-4-phenylmethoxybenzoate Chemical compound C1=C([N+]([O-])=O)C(C(=O)OC)=CC(OC)=C1OCC1=CC=CC=C1 GUOGVJFNFLXSLK-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
230000035772 mutation Effects 0.000 description 1
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
208000003786 myxedema Diseases 0.000 description 1
LISJBCSAHJLTSF-UHFFFAOYSA-N n-[3-(1,3-benzothiazol-2-yl)phenyl]-4-(4-methylpiperazin-1-yl)pyrimidin-2-amine Chemical compound C1CN(C)CCN1C1=CC=NC(NC=2C=C(C=CC=2)C=2SC3=CC=CC=C3N=2)=N1 LISJBCSAHJLTSF-UHFFFAOYSA-N 0.000 description 1
YDSXSZMCTDECQQ-UHFFFAOYSA-N n-[3-(1,3-benzothiazol-2-yl)phenyl]-6,7-dimethoxyquinazolin-4-amine Chemical compound C1=CC=C2SC(C=3C=CC=C(C=3)NC=3N=CN=C4C=C(C(=CC4=3)OC)OC)=NC2=C1 YDSXSZMCTDECQQ-UHFFFAOYSA-N 0.000 description 1
MUCYAODTPGRAAJ-UHFFFAOYSA-N n-[3-(1,3-benzothiazol-2-yl)phenyl]-7-chloroquinolin-4-amine Chemical compound C1=CC=C2SC(C=3C=CC=C(C=3)NC=3C4=CC=C(C=C4N=CC=3)Cl)=NC2=C1 MUCYAODTPGRAAJ-UHFFFAOYSA-N 0.000 description 1
SRCAIQMBBDVLGX-UHFFFAOYSA-N n-[3-(1,3-benzothiazol-2-yl)phenyl]-7h-purin-6-amine Chemical compound C=1C=CC(C=2SC3=CC=CC=C3N=2)=CC=1NC1=NC=NC2=C1N=CN2 SRCAIQMBBDVLGX-UHFFFAOYSA-N 0.000 description 1
BMGGDZTXJBWQCN-UHFFFAOYSA-N n-[3-(1,3-benzothiazol-2-yl)phenyl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C=1C=CC(C=2SC3=CC=CC=C3N=2)=CC=1NC1=NC=NC2=C1C=CN2 BMGGDZTXJBWQCN-UHFFFAOYSA-N 0.000 description 1
MSRRUEAJHJBOGH-UHFFFAOYSA-N n-[3-(1,3-benzothiazol-2-yl)phenyl]pyridin-4-amine Chemical compound C=1C=CC(C=2SC3=CC=CC=C3N=2)=CC=1NC1=CC=NC=C1 MSRRUEAJHJBOGH-UHFFFAOYSA-N 0.000 description 1
KMOJBMHGVSKOIC-UHFFFAOYSA-N n-[3-(1,3-benzothiazol-2-yl)phenyl]thieno[3,2-d]pyrimidin-4-amine Chemical compound C=1C=CC(C=2SC3=CC=CC=C3N=2)=CC=1NC1=NC=NC2=C1SC=C2 KMOJBMHGVSKOIC-UHFFFAOYSA-N 0.000 description 1
OPMIDUGTYQLEGT-UHFFFAOYSA-N n-[4-(1,3-benzothiazol-2-yl)-2-fluorophenyl]-7-chloroquinolin-4-amine Chemical compound C1=CC=C2SC(C=3C=C(C(=CC=3)NC=3C4=CC=C(Cl)C=C4N=CC=3)F)=NC2=C1 OPMIDUGTYQLEGT-UHFFFAOYSA-N 0.000 description 1
RSIMWZIJZCXPJV-UHFFFAOYSA-N n-[4-(1,3-benzothiazol-2-yl)-2-fluorophenyl]thieno[3,2-d]pyrimidin-4-amine Chemical compound C1=CC=C2SC(C=3C=C(C(=CC=3)NC=3C=4SC=CC=4N=CN=3)F)=NC2=C1 RSIMWZIJZCXPJV-UHFFFAOYSA-N 0.000 description 1
WSYQREDUJBEDRJ-UHFFFAOYSA-N n-[4-(1,3-benzothiazol-2-yl)-3-chlorophenyl]-7-chloroquinolin-4-amine Chemical compound C1=CC=C2SC(C3=CC=C(C=C3Cl)NC=3C4=CC=C(C=C4N=CC=3)Cl)=NC2=C1 WSYQREDUJBEDRJ-UHFFFAOYSA-N 0.000 description 1
LRLIJRSPYLLOIV-UHFFFAOYSA-N n-[4-(1,3-benzothiazol-2-yl)-3-chlorophenyl]thieno[3,2-d]pyrimidin-4-amine Chemical compound C1=CC=C2SC(C3=CC=C(NC=4C=5SC=CC=5N=CN=4)C=C3Cl)=NC2=C1 LRLIJRSPYLLOIV-UHFFFAOYSA-N 0.000 description 1
KLXVOIRVJURYJX-UHFFFAOYSA-N n-[4-(1,3-benzothiazol-2-yl)-3-methoxyphenyl]-7-chloroquinolin-4-amine Chemical compound C1=CC=C2SC(C3=CC=C(NC=4C5=CC=C(Cl)C=C5N=CC=4)C=C3OC)=NC2=C1 KLXVOIRVJURYJX-UHFFFAOYSA-N 0.000 description 1
DPBAOWACXDVJKP-UHFFFAOYSA-N n-[4-(1,3-benzothiazol-2-yl)-3-methoxyphenyl]-7h-purin-6-amine Chemical compound C1=CC=C2SC(C3=CC=C(NC=4C=5NC=NC=5N=CN=4)C=C3OC)=NC2=C1 DPBAOWACXDVJKP-UHFFFAOYSA-N 0.000 description 1
JITVDYOPSHDJPS-UHFFFAOYSA-N n-[4-(1,3-benzothiazol-2-yl)-3-methoxyphenyl]pyridin-4-amine Chemical compound C=1C=C(C=2SC3=CC=CC=C3N=2)C(OC)=CC=1NC1=CC=NC=C1 JITVDYOPSHDJPS-UHFFFAOYSA-N 0.000 description 1
YVZHTPUIVFSOKV-UHFFFAOYSA-N n-[4-(1,3-benzothiazol-2-yl)-3-methoxyphenyl]thieno[3,2-d]pyrimidin-4-amine Chemical compound C1=CC=C2SC(C3=CC=C(NC=4C=5SC=CC=5N=CN=4)C=C3OC)=NC2=C1 YVZHTPUIVFSOKV-UHFFFAOYSA-N 0.000 description 1
KRNIYGNHGYXWAF-UHFFFAOYSA-N n-[4-(1,3-benzothiazol-2-yl)phenyl]-2-chloropyridin-4-amine Chemical compound C1=NC(Cl)=CC(NC=2C=CC(=CC=2)C=2SC3=CC=CC=C3N=2)=C1 KRNIYGNHGYXWAF-UHFFFAOYSA-N 0.000 description 1
NKFMXSGKHGALAU-UHFFFAOYSA-N n-[4-(1,3-benzothiazol-2-yl)phenyl]-7-chloro-6-methoxyquinazolin-4-amine Chemical compound C1=CC=C2SC(C3=CC=C(C=C3)NC3=C4C=C(C(=CC4=NC=N3)Cl)OC)=NC2=C1 NKFMXSGKHGALAU-UHFFFAOYSA-N 0.000 description 1
IFTCXKUSJMWVRD-UHFFFAOYSA-N n-[4-(1,3-benzothiazol-2-yl)phenyl]-7-chloroquinolin-4-amine Chemical compound C1=CC=C2SC(C3=CC=C(C=C3)NC=3C4=CC=C(C=C4N=CC=3)Cl)=NC2=C1 IFTCXKUSJMWVRD-UHFFFAOYSA-N 0.000 description 1
VANNKDNVAYXPGI-UHFFFAOYSA-N n-[4-(1,3-benzothiazol-2-yl)phenyl]-7h-purin-6-amine Chemical compound C=1C=C(C=2SC3=CC=CC=C3N=2)C=CC=1NC1=NC=NC2=C1N=CN2 VANNKDNVAYXPGI-UHFFFAOYSA-N 0.000 description 1
CZUVMGAHFHQKLM-UHFFFAOYSA-N n-[4-(1,3-benzothiazol-2-yl)phenyl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C=1C=C(C=2SC3=CC=CC=C3N=2)C=CC=1NC1=NC=NC2=C1C=CN2 CZUVMGAHFHQKLM-UHFFFAOYSA-N 0.000 description 1
ZCGDFAQAYLXLJV-UHFFFAOYSA-N n-[4-(1,3-benzothiazol-2-yl)phenyl]thieno[3,2-d]pyrimidin-4-amine Chemical compound C=1C=C(C=2SC3=CC=CC=C3N=2)C=CC=1NC1=NC=NC2=C1SC=C2 ZCGDFAQAYLXLJV-UHFFFAOYSA-N 0.000 description 1
QDTDFSFRIDFTCF-UHFFFAOYSA-N n-phenyl-1,3-benzothiazol-2-amine Chemical compound N=1C2=CC=CC=C2SC=1NC1=CC=CC=C1 QDTDFSFRIDFTCF-UHFFFAOYSA-N 0.000 description 1
235000021096 natural sweeteners Nutrition 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
208000009928 nephrosis Diseases 0.000 description 1
231100001027 nephrosis Toxicity 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000012038 nucleophile Substances 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
238000010534 nucleophilic substitution reaction Methods 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
201000005737 orchitis Diseases 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000008012 organic excipient Substances 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 1
125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 description 1
125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 1
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
201000001976 pemphigus vulgaris Diseases 0.000 description 1
125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
230000008823 permeabilization Effects 0.000 description 1
125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
238000003566 phosphorylation assay Methods 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000007180 physiological regulation Effects 0.000 description 1
229940081066 picolinic acid Drugs 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
239000011505 plaster Substances 0.000 description 1
108010056274 polo-like kinase 1 Proteins 0.000 description 1
201000006292 polyarteritis nodosa Diseases 0.000 description 1
208000030428 polyarticular arthritis Diseases 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
208000006473 polyradiculopathy Diseases 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
108010027883 protein kinase C eta Proteins 0.000 description 1
108010008359 protein kinase C lambda Proteins 0.000 description 1
230000022558 protein metabolic process Effects 0.000 description 1
CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
208000009954 pyoderma gangrenosum Diseases 0.000 description 1
125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
230000005855 radiation Effects 0.000 description 1
206010061928 radiculitis Diseases 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000031539 regulation of cell division Effects 0.000 description 1
230000018866 regulation of programmed cell death Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229960004181 riluzole Drugs 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
238000003118 sandwich ELISA Methods 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 1
CGRKYEALWSRNJS-UHFFFAOYSA-N sodium;2-methylbutan-2-olate Chemical compound [Na+].CCC(C)(C)[O-] CGRKYEALWSRNJS-UHFFFAOYSA-N 0.000 description 1
229940075554 sorbate Drugs 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
108010087686 src-Family Kinases Proteins 0.000 description 1
102000009076 src-Family Kinases Human genes 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
230000000475 sunscreen effect Effects 0.000 description 1
239000000516 sunscreening agent Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
238000009210 therapy by ultrasound Methods 0.000 description 1
VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 1
230000008719 thickening Effects 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
208000008732 thymoma Diseases 0.000 description 1
GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 1
FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000030968 tissue homeostasis Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 description 1
YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical compound BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
235000019798 tripotassium phosphate Nutrition 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000011345 viscous material Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000001262 western blot Methods 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

CA002615420A 2005-07-15 2006-05-16 2-arylbenzothiazoles et leurs utilisations Abandoned CA2615420A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP05015432A EP1746096A1 (fr)	2005-07-15	2005-07-15	Analogues de 2-arylbenzothiazole utiles comme agents anticancereux
EP05015432.7		2005-07-15
PCT/EP2006/004620 WO2007009524A1 (fr)	2005-07-15	2006-05-16	2-arylbenzothiazoles et leurs utilisations

Publications (1)

Publication Number	Publication Date
CA2615420A1 true CA2615420A1 (fr)	2007-01-25

Family

ID=39264354

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002615420A Abandoned CA2615420A1 (fr)	2005-07-15	2006-05-16	2-arylbenzothiazoles et leurs utilisations

Country Status (3)

Country	Link
EP (1)	EP1910349A1 (fr)
JP (1)	JP2009501164A (fr)
CA (1)	CA2615420A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN116262730A (zh) *	2021-12-14	2023-06-16	烟台京师材料基因组工程研究院	一种含羟基三芳胺的化合物及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CR20160494A (es) *	2014-04-25	2016-12-20	Pfizer	Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
IL307931A (en) *	2016-04-15	2023-12-01	Epizyme Inc	Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
HUE063405T2 (hu) *	2016-12-19	2024-01-28	Epizyme Inc	Amin-szubsztituált heterociklusos vegyületek, mint EHMT2 inhibitorok és felhasználásuk módszerei
JP7702165B2 (ja) *	2021-05-03	2025-07-03	ジェービーケーラボカンパニーリミテッド	がんの予防、緩和、または処置のための医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9914258D0 (en) *	1999-06-18	1999-08-18	Celltech Therapeutics Ltd	Chemical compounds
US20030144308A1 (en) *	2001-09-24	2003-07-31	Bauer Paul H.	Fructose 1,6-bisphosphatase inhibitors
EP1542997B1 (fr) *	2002-07-24	2012-02-29	Dermira (Canada), Inc.	Derives de pyrazolylbenzothiazole et leur utilisation en tant qu' agents therapeutiques
AU2003298306A1 (en) *	2002-11-22	2004-06-18	Walter Snoeijs	Track and hold circuit
EP1605946B1 (fr) *	2003-03-25	2008-05-28	Vertex Pharmaceuticals Incorporated	Thiazoles utiles en tant qu'inhibiteurs des proteines kinases

2006
- 2006-05-16 CA CA002615420A patent/CA2615420A1/fr not_active Abandoned
- 2006-05-16 EP EP06753651A patent/EP1910349A1/fr not_active Withdrawn
- 2006-05-16 JP JP2008520728A patent/JP2009501164A/ja active Pending

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN116262730A (zh) *	2021-12-14	2023-06-16	烟台京师材料基因组工程研究院	一种含羟基三芳胺的化合物及其应用

Also Published As

Publication number	Publication date
JP2009501164A (ja)	2009-01-15
EP1910349A1 (fr)	2008-04-16

Legal Events

Date	Code	Title	Description
2012-05-16	FZDE	Discontinued

Publication	Publication Date	Title
US20070021446A1 (en)	2007-01-25	2-arylbenzothiazole analogues and uses thereof
US20090270410A1 (en)	2009-10-29	Benzazole analogues and uses thereof
US20070149523A1 (en)	2007-06-28	Thiazole Analogues and Uses Thereof
EP1785420A1 (fr)	2007-05-16	Analogues de thiazole et leurs utilisation
TWI423805B (zh)	2014-01-21	Ｐ７０ｓ６激酶抑制劑
IL319953A (en)	2025-05-01	Preparations for the treatment of tumors with a KRAS mutation
CA2775942A1 (fr)	2011-04-07	Inhibiteurs selectifs de la pi3k (delta)
WO2010056320A2 (fr)	2010-05-20	Inhibiteurs de la pi3k/mtor kinase
CA2592509C (fr)	2015-02-17	Analogues du benzazole et leurs utilisations
JP2009529556A (ja)	2009-08-20	ＮＦ−κＢ阻害薬（プロテアソーム阻害薬）としてのチアゾール
JP2024502178A (ja)	2024-01-17	Ｓｇｋ－１を阻害するためのピラゾロ［３，４－ｄ］ピリミジン－６－イル－スルホンアミド誘導体
EP1885719A1 (fr)	2008-02-13	Derivés benzazoles 2,5- et 2,6-disubstitués utiles comme des inhibiteurs de la proteine kinase
JP2009529555A (ja)	2009-08-20	新規複素環式ＮＦ−κＢ阻害薬
EP1910349A1 (fr)	2008-04-16	2-arylbenzothiazoles et leurs utilisations
US7514460B2 (en)	2009-04-07	Benzazole analogues and uses thereof
CA3195542A1 (fr)	2022-04-21	Composes bicycliques
AU2021284676A1 (en)	2023-02-02	New pyrazine compound
HK1110584A (en)	2008-07-18	2, 5 and 2, 6-disubstituted benzazole analogues useful as protein kinase inhibitors
CN120457122A (zh)	2025-08-08	微管蛋白聚合抑制剂
CN119707984A (zh)	2025-03-28	吡唑并三嗪及吡唑并嘧啶衍生物、其制备方法、药物组合物及其用途

CA2615420A1 - 2-arylbenzothiazoles et leurs utilisations - Google Patents

Info

Links

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=39264354

Family Applications (1)

Country Status (3)

Cited By (1)

Families Citing this family (4)

Family Cites Families (5)

Cited By (1)

Also Published As

Similar Documents

Legal Events